摘要
背景:自噬是一种通过消除受损或无用的细胞成分来维持细胞内稳态的细胞途径,其解除管制可能引发或加重。吃不同的人类疾病。黄酮类化合物是一组植物代谢物,能够调节包括自噬在内的不同的分子和细胞过程。 目的:综述黄酮类化合物对侵袭性和非侵袭性人类疾病自噬途径的影响,重点探讨其在疾病进展中的全球作用。此外,并对黄酮类化合物与药物或其他天然无毒化合物的组合进行了综述。 方法:进行文献检索,以鉴定和分析同行评议的文献,其中包括体内外研究,重点是不同增殖期和非增殖期的自噬解除管制。黄酮类化合物对增殖的作用及潜在的保护作用。 结果:文献分析表明,自噬改变引起的细胞死亡与存活失衡在多种人类疾病的病理生理过程中起着重要作用。大使用不同的黄酮类化合物作为自噬调节剂,单独或与其他分子结合使用,可能是治疗癌症、神经退行性疾病、心血管疾病的一种有价值的策略。疾病,肝病,利什曼病,流感,胃溃疡产生幽门螺杆菌感染,糖尿病,哮喘,年龄相关性黄斑变性或骨质疏松症。 结论:黄酮类化合物有可能成为治疗自噬性解除管制相关疾病的重要辅助药物。此外,联合疗法可能会有所帮助。减少这些常规治疗的剂量,减少药物衍生物副作用,提高患者的生存率。
关键词: 黄酮类化合物,自噬,癌症,神经退行性疾病,心血管疾病,肝脏疾病,传染病,糖尿病。
Current Medicinal Chemistry
Title:Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Volume: 25 Issue: 7
关键词: 黄酮类化合物,自噬,癌症,神经退行性疾病,心血管疾病,肝脏疾病,传染病,糖尿病。
摘要: Background: Autophagy is a cellular pathway with the ability to maintain cell homeostasis through the elimination of damaged or useless cellular components, and its deregulation may initiate or aggravate different human diseases. Flavonoids, a group of plant metabolites, are able to modulate different molecular and cellular processes including autophagy.
Objective: To review the effects of flavonoids on autophagy pathway in both invasive and noninvasive human diseases, focusing on the global outcomes in their progression. Moreover, the efficacy of the combination of flavonoids with drugs or other natural nontoxic compounds was also reviewed.
Methods: A literature search was performed to identify and analyze peer-reviewed publications containing in vitro and in vivo studies focused on autophagy deregulation in different proliferative and non-proliferative pathologies and the potential protective effects of flavonoids.
Results: Analyzed publications indicated that imbalance between cell death and survival induced by changes in autophagy play an important role in the pathophysiology of a number of human diseases. The use of different flavonoids as autophagy modulators, alone or in combination with other molecules, might be a worthy strategy in the treatment of cancer, neurodegenerative disorders, cardiovascular diseases, hepatic diseases, leishmaniasis, influenza, gastric ulcers produced by Helicobacter pylori infection, diabetes, asthma, age-related macular degeneration or osteoporosis.
Conclusion: Flavonoids could potentially constitute important adjuvant agents of conventional therapies in the treatment of autophagy deregulation-related diseases. Moreover, combined therapy may help to diminish the doses of those conventional treatments, leading to reduced drug-derivative side effects and to improved patients' survival.
Export Options
About this article
Cite this article as:
Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease, Current Medicinal Chemistry 2018; 25 (7) . https://dx.doi.org/10.2174/0929867324666170918125155
DOI https://dx.doi.org/10.2174/0929867324666170918125155 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure in South America
Current Cardiology Reviews Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design The Therapeutic Potential of Bone Marrow Mesenchymal Stem Cells for Articular Cartilage Regeneration in Osteoarthritis
Current Stem Cell Research & Therapy Phosphorylated and O-GlcNAc Modified IRS-1 (Ser1101) and -2 (Ser1149) Contribute to Human Diabetes Type II
Protein & Peptide Letters Editorial (Thematic Issue: Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From Molecular Level to Nanotechnology)
Current Pharmaceutical Design Amniotic Fluid Embolism: Review
Current Pharmaceutical Biotechnology Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design TSH Variations in Chronic Heart Failure Outpatients: Clinical Correlates and Outcomes
Endocrine, Metabolic & Immune Disorders - Drug Targets Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
Current Medicinal Chemistry